| Popis: |
1. Cytoprotection, using radioprotectors, is mandatory to improve the therapeutic ratio of RT and RCT. 2. The ideal radioprotector needs to have a wide spectrum of protection against toxicity, without interfering in the tumour response while having an acceptable toxicity and cost-benefit profile. To-date, the sulphydryl compounds are the best radioprotectors available, for clinical practice. 3. Amifostine is indicated in the prevention of radiation-induced xerostomia and of mucositis in tumours of head & neck treated with RT or with RCT. 4. New biological agents for use in combination with amifostine are currently under investigation to optimize and amplify the clinical indications for use of radioprotectors. |
Full text from SpringerLink